Reference(s)
Click here to return to the Reference Table

Cancer type: Osteosarcoma


HGF/SF expression

Reference Number: 141
Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48, 757-62 (1998).
PubMed link      E-mail link

Reference Number: 820
Chattopadhyay N, MacLeod RJ, Tfelt-Hansen J, Brown EM. 1alpha,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells. Am J Physiol Endocrinol Metab. 284, E219-27 (2003)
PubMed link      E-mail link

Reference Number: 821
Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC, Kirpensteijn J. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 46, 869-77 (2009)
PubMed link      E-mail link

Reference Number: 990
Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, Kidera Y, Moriyama K, Nishida S. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-ß as angiogenic factors in mouse osteosarcoma. Cytokine. 54, 100-7 (2011)
PubMed link      E-mail link

Reference Number: 1128
Zhang L, Wang Y, Wang L, Cao T, Hyuga S, Sato T, Wu Y, Yamagata S, Yamagata T. Ganglioside GD1a negatively regulates hepatocyte growth factor expression through caveolin-1 at the transcriptional level in murine osteosarcoma cells. Biochim Biophys Acta. 1810, 759-68 (2011)
PubMed link      E-mail link

Reference Number: 1805
Husmann K, Ducommun P, Sabile AA, Pedersen EM, Born W, Fuchs B. Signal transduction and downregulation of C-MET in HGF stimulated low and highly metastatic human osteosarcoma cells. Biochem Biophys Res Commun. 464, 1222-7 (2015)
PubMed link      E-mail link

Met expression

Reference Number: 138
Rong, S. et al. Met expression and sarcoma tumorigenicity. Cancer Res 53, 5355-60 (1993).
PubMed link      E-mail link

Reference Number: 141
Fukuda, T. et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 48, 757-62 (1998).
PubMed link      E-mail link

Reference Number: 142
Arihiro, K. & Inai, K. Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma. Pathol Int 51, 100-6 (2001).
PubMed link      E-mail link

Reference Number: 143
Ferracini, R. et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-49 (1995).
PubMed link      E-mail link

Reference Number: 144
Oda, Y., Naka, T., Takeshita, M., Iwamoto, Y. & Tsuneyoshi, M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 31, 709-16 (2000).
PubMed link      E-mail link

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

Reference Number: 819
Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K, Ferracini R. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 17, 1162-4 (2003)
PubMed link      E-mail link

Reference Number: 821
Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC, Kirpensteijn J. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 46, 869-77 (2009)
PubMed link      E-mail link

Reference Number: 1059
Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, Geller DS. Cell surface receptor expression patterns in osteosarcoma. Cancer. 118, 740-9 (2012)
PubMed link      E-mail link

Reference Number: 1127
Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O'Keefe RJ, Rosier RN. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 26, 1283-94 (2011)
PubMed link      E-mail link

Reference Number: 1198
Dani N, Olivero M, Mareschi K, van Duist MM, Miretti S, Cuvertino S, Patané S, Calogero R, Ferracini R, Scotlandi K, Fagioli F, Di Renzo MF. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. J Bone Miner Res. 27, 1322-34 (2012)
PubMed link      E-mail link

Reference Number: 1202
Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, Ma B. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One. 7, e33778 (2012)
PubMed link      E-mail link

Reference Number: 1411
Novello C1, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P, Benassi MS. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 42, 667-75 (2013)
PubMed link      E-mail link

Reference Number: 1663
Niu G, Li B, Sun J, Sun L. miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met. Cell Prolif. 48, 348-55 (2015)
PubMed link      E-mail link

Reference Number: 1767
Jiang C, Chen H, Shao L, Wang Q MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31. Oncol Rep. 32, 1249-56 (2014)
PubMed link      E-mail link

Reference Number: 1805
Husmann K, Ducommun P, Sabile AA, Pedersen EM, Born W, Fuchs B. Signal transduction and downregulation of C-MET in HGF stimulated low and highly metastatic human osteosarcoma cells. Biochem Biophys Res Commun. 464, 1222-7 (2015)
PubMed link      E-mail link

Poor Prognosis

Mutation of Met

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

In vitro studies

Reference Number: 143
Ferracini, R. et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10, 739-49 (1995).
PubMed link      E-mail link

Reference Number: 265
MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH, Radinsky R. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 20:421-30 (2003).
PubMed link      E-mail link

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

Reference Number: 819
Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K, Ferracini R. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J. 17, 1162-4 (2003)
PubMed link      E-mail link

Reference Number: 823
Cantiani L, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res. 67, 7675-85 (2007)
PubMed link      E-mail link

Reference Number: 1502
McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CA. Met interacts with EGFR and Ron in canine osteosarcoma. Vet Comp Oncol. 11, 124-39 (2013)
PubMed link      E-mail link

Animal models

Reference Number: 145
Ferracini, R. et al. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 18, 253-6. (2000).
PubMed link      E-mail link

Reference Number: 821
Fieten H, Spee B, Ijzer J, Kik MJ, Penning LC, Kirpensteijn J. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. Vet Pathol. 46, 869-77 (2009)
PubMed link      E-mail link

Reference Number: 822
De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Biolatti B, Levine RA, Buracco P, Di Renzo MF.
met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol. 218, 399-408 (2009)

PubMed link      E-mail link

Reference Number: 990
Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, Kidera Y, Moriyama K, Nishida S. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-ß as angiogenic factors in mouse osteosarcoma. Cytokine. 54, 100-7 (2011)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

Reference Number: 1112
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther. 11, 1223-32 (2011)
PubMed link      E-mail link

Reference Number: 1127
Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O'Keefe RJ, Rosier RN. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 26, 1283-94 (2011)
PubMed link      E-mail link

Reference Number: 1231
Wang K, Zhuang Y, Liu C, Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch Biochem Biophys. 526, 38-43 (2012)
PubMed link      E-mail link

Reviews